,7,8,9,10 Multiple studies have validated the effectiveness of the combination of above CDK 4/6 inhibitors with ET in HR+/HER2-breast cancer, demonstrating prolonged progression-free survival and overall survival, alongside reduced recurrence risk compared to ET alone.11 Here, ERBB2 is linked to breast cancer.